Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending Dose Study of the Clinical Activity, Safety, Tolerability and Pharmacokinetics of a Single IV Dose of REGN846 in Refractory Moderate-to-Severe Pruritus in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 24 Apr 2014
Price :
$35
*
At a glance
- Drugs REGN 846 (Primary)
- Indications Atopic dermatitis; Pruritus
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 24 Apr 2014 New trial record